NeoGen Labs

What NeoGen Labs does

NeoGen Labs (NeoGen Labs Pvt. Ltd.) is a Bangalore-based clinical diagnostics laboratory founded in June 2006 by Thomas Mookken and Dr. Rohit Cariappa. It operates a single CAP- and NABL-accredited facility out of Lingarajapuram, Bangalore, and provides the First Step Newborn Screening Test — a preventive diagnostic service that screens newborns, ideally 24–72 hours after birth, for Inborn Errors of Metabolism and related treatable metabolic disorders using dried blood spot samples collected on CLSI-compliant barcoded filter paper. The service is offered primarily to parents of newborns and to the doctors and hospitals that order the test on their behalf.

The core of the technical platform is Tandem Mass Spectrometry (MS/MS) used for acylcarnitine and amino acid profiling, combined with biochemical assays covering congenital hypothyroidism, congenital adrenal hyperplasia, G6PD deficiency, galactosemia, biotinidase deficiency, phenylketonuria, cystic fibrosis, hemoglobinopathies, and spinal muscular atrophy. The First Step menu screens for 50+ disorders aligned with the U.S. Recommended Uniform Screening Panel. Interpretation of MS/MS results is grounded in a proprietary reference dataset built up over the screening of more than 4 million babies, and the lab's analytical methods sit on a Technology Licensing Agreement with Revvity (formerly PerkinElmer Genomics / Pediatrix Screening), augmented by 18 years of in-house enhancements. Certain specialized tests are routed to PerkinElmer Genetics Lab in Bridgeville, PA, when requested.

Commercially, NeoGen Labs runs a B2B2C model. Hospitals, obstetricians, and pediatricians are the primary order channel, with samples shipped to the Bangalore lab for processing and turnaround typically within the same or next day; parents can also order directly through the company's website. Pricing is not publicly disclosed and the company is privately held, with no external institutional funding, acquisitions, or geographic expansion beyond India identified in available sources. Quality standing is reinforced by participation in the CDC's Newborn Screening Quality Assurance Program (NSQAP), placing the lab within a global reference network of 650+ screening laboratories across 75 countries.

Name

NeoGen Labs

Legal name

NeoGen Labs Pvt. Ltd.

Website

https://neogenlabs.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

NeoGen Labs is a Bangalore-based, CAP- and NABL-accredited clinical laboratory that screens newborns 24–72 hours after birth for over 50 treatable Inborn Errors of Metabolism via the First Step test using Tandem Mass Spectrometry and biochemical analysis on dried blood spots, serving parents and ordering physicians across India.

Ownership category

akta.pro rank

Product category

Unknown

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

akta.pro secondary industry

Central Laboratory Services (Core Lab Operations) (HLAGAEAA)

Keywords

• Technology products
• Software solutions
• Research services
• Data solutions
• Digital platforms

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Clinical Diagnostic Laboratory Services: NeoGen Labs generates revenue through providing clinical diagnostic testing services for newborn screening. Samples are collected via dried blood spot and analyzed using Tandem Mass Spectrometry and biochemical analysis to detect metabolic disorders.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

No detailed information about NeoGen Labs' core offerings was provided in the input data.

Product overview

NeoGen Labs offers a single unified diagnostic service called the First Step Newborn Screening Test. The core offering is a newborn metabolic disorder screening program that combines two complementary analysis methods: Tandem Mass Spectrometry (MS/MS) for acylcarnitine and amino acid profiling, and biochemical analysis for other conditions. The company operates a single laboratory facility in Bangalore, India, with samples collected via dried blood spots on filter paper and processed with same-day or next-day turnaround times. Some specialized tests are referred to PerkinElmer Genetics Lab in the USA.

Differentiator

Problem solved

Functional benefit

Brands

• First Step Newborn Screening Program: The primary screening program offered by NeoGen Labs that screens newborns for Inborn Errors of Metabolism (IEMs) and metabolic disorders using dried blood spot samples.

Segments2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Revvity (formerly PerkinElmer Genomics and Pediatrix Screening)coreTechnology or IntegrationRevvity is the world's leading company in Newborn Screening. NeoGen Labs entered into a Technology Licensing Agreement with Revvity and has built proprietary enhancements on this technology based on 18 years of experience screening infants. Some additional tests are performed at PerkinElmer Genetics Lab in Bridgeville, PA, USA when requested.
• EBF (Eleveland Biomedical)coreOEM/ Whitelabel/ Licensing PartnerEBF holds worldwide rights for 903 filter paper for NBS and custom manufactures the filter paper collection forms (903 or 226 filter paper blood collection forms) specifically for NeoGen Labs. These are bar coded and manufactured to be compliant with CLSI Standards.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Regional players

• Agappe Diagnostics: Agappe is an Indian IVD and clinical chemistry company that supplies reagents and instruments, including for neonatal screening workflows. It is a regional competitor for hospital and laboratory customers in the Indian diagnostics market.
• Trivitron Healthcare: Trivitron is a leading Indian medical technology and in-vitro diagnostics company with neonatal screening and clinical chemistry offerings. It serves the same Indian hospital customer base as NeoGen Labs and competes in newborn metabolic screening reagents/instruments.

Broad incumbents

• Revvity: Revvity (formerly PerkinElmer Genomics / Pediatrix Screening) is the global leader in newborn screening and is NeoGen Labs' core technology licensor. It offers a directly comparable MS/MS-based NBS platform globally and is the strategic counterparty whose moves most directly shape NeoGen's economics.
• Quest Diagnostics: Quest Diagnostics is a large U.S. clinical laboratory services provider that performs newborn screening and pediatric metabolic testing as part of a much broader diagnostic menu. It represents the scaled, incumbent version of the clinical lab services model NeoGen operates in India.
• Laboratory Corporation of America (Labcorp): Labcorp is a global clinical laboratory network with pediatric and rare disease testing capabilities, including newborn screening-adjacent diagnostics. It is a broad incumbent comparable on business model and laboratory services delivery.

Direct peers

• Baebies: Baebies is a U.S.-based diagnostics company focused on newborn screening using proprietary platform technology (FISH/FLOW and digital microfluidics) and screening panels for IEMs. It is a direct product-and-use-case peer in the global private NBS market.

Emerging players

• Strand Life Sciences: Strand Life Sciences is an Indian genomics and clinical diagnostics provider offering hereditary, prenatal, and rare disease testing. It competes with NeoGen Labs for clinician-driven genetic and metabolic test orders in India.
• Natera: Natera is a U.S. genetic testing company with reproductive health and pediatric genetic screening products. It overlaps with NeoGen in the reproductive and pediatric genetic screening segment using dried blood spot / buccal sample workflows.
• Centogene: Centogene is a rare disease diagnostics company offering biochemical and genetic testing, including newborn and pediatric metabolic disorder panels. It is comparable to NeoGen Labs on the IEM / rare disease testing use case and the cross-border dried blood spot sample model.
• MedGenome: MedGenome is an India-headquartered genomics and molecular diagnostics company with carrier screening, prenatal, and rare disease panels. It overlaps with NeoGen on the genetic/rare-disease portion of the NBS workflow and competes for the same physician referral channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/neogenlabs
• Facebookfacebook.com/NeoGenLabs
• LinkedInlinkedin.com/company/neogen-labs-pvt-ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeoGen Labs